Mechanistically, SHP2 inhibition reduced the number of immature T cells, restored overactivated ERK/MAPK signaling, and decreased the production of IFN-γ and IL-17A/F in T cells, two cytokines involved in SLE.40 The gene discussed is IL17A; the disease is systemic lupus erythematosus.